Offerings - Offering: 1 |
Apr. 30, 2026
USD ($)
shares
|
|---|---|
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common Stock, par value $0.001 per share |
| Amount Registered | shares | 9,723,057 |
| Proposed Maximum Offering Price per Unit | 0.28 |
| Maximum Aggregate Offering Price | $ 2,722,455.96 |
| Fee Rate | 0.01381% |
| Amount of Registration Fee | $ 375.97 |
| Offering Note | (1) Represents shares of Common Stock, par value $0.001 per share ("Common Stock"), of GT Biopharma, Inc. (the "Company"), which consists of (i) 4,527,654 shares of Common Stock issuable upon the conversion of 2,055.5554 shares of Series L 10% Convertible Preferred Stock, par value $0.001 per share (the "Series L Preferred Stock"), (ii) 4,527,654 shares of Common Stock issuable upon the exercise of vested warrants issuable upon exercise of the Greenshoe Rights (as defined in the Registration Statement), (iii) 267,749 shares of Common Stock issued to the holders of Series L Preferred Stock of record as of March 19, 2026 as a dividend, which represents 10% of the outstanding stated value of the Series L Preferred Stock, payable on April 1, 2026, and (iv) 400,000 shares of Common Stock issuable upon the exercise of pre-funded warrants, offered for resale by the selling stockholders pursuant to the prospectus contained in this Registration Statement on Form S-1. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of common stock issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction. (2) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act. The price per share and aggregate offering price are based on the average of the high and low prices of the registrant's Common Stock on April 28, 2026, as reported on The Nasdaq Capital Market. |